---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-318069"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2026-07-27T20:08:03+00:00"
generated_at: "2026-07-27T20:09:15.011429+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q2 2026 net loss narrows to $8.4M; provides FY 2026 revenue guidance $560-585M

## Summary
- Consolidated revenue $163.5M vs $156.8M YoY; operating loss improved to $7.0M from $60.0M.
- Net loss $8.4M ($0.01/share) vs $148.4M ($0.19/share) in Q2 2025.
- Diagnostics revenue $74.5M (down from $101.1M due to oncology asset sale to Labcorp); pharma product revenue $42.9M.
- Cash and equivalents $314.4M; $105.3M of stock repurchased under $200M program.
- FY 2026 total revenue guidance $560-585M; Q3 2026 revenue guidance $131-142M.

## SEC filing metadata
- accession: 0001193125-26-318069
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2026-07-27T20:08:03+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/0001193125-26-318069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/opk-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-318069
- JSON: https://secwatch.observer/filing/0001193125-26-318069.json
- Plain text: https://secwatch.observer/filing/0001193125-26-318069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.